Literature DB >> 11238743

Complete inhibition of in vivo glioma growth by oncostatin M.

M Friedrich1, N Höss, F Stögbauer, V Senner, W Paulus, E B Ringelstein, H Halfter.   

Abstract

We describe here the oncostatin M (OSM)-dependent inhibition of in vivo tumour formation after intracerebral inoculation of glioblastoma cells in mice. We generated human glioblastoma cells transfected with the OSM gene under the control of a tetracycline-response promoter. Upon removal of tetracycline from the medium, cells exhibited a differentiated cell morphology, while proliferation was significantly inhibited. After implantation of these cells into nude mice brains, large tumours developed in animals lacking OSM expression, whereas no tumour formation was observed in mice with induced OSM expression. Our results suggest that OSM exerts pronounced antitumorigenic effects on glioblastoma cells in vivo and provide arguments for a therapeutic application of OSM in humans.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11238743     DOI: 10.1046/j.1471-4159.2001.00202.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  8 in total

1.  Overexpression of a splice variant of oncostatin M receptor beta in human esophageal squamous carcinoma.

Authors:  Tasneem Kausar; Rinu Sharma; Md Raghibul Hasan; Anoop Saraya; Tushar K Chattopadhyay; Siddartha Datta Gupta; Ranju Ralhan
Journal:  Cell Oncol (Dordr)       Date:  2011-03-11       Impact factor: 6.730

2.  Genomic events associated with progression of pleural malignant mesothelioma.

Authors:  Sergey V Ivanov; Jeremy Miller; Robert Lucito; Chunlao Tang; Alla V Ivanova; Jianming Pei; Michele Carbone; Christina Cruz; Amanda Beck; Craig Webb; Daisuke Nonaka; Joseph R Testa; Harvey I Pass
Journal:  Int J Cancer       Date:  2009-02-01       Impact factor: 7.396

3.  Oncostatin-M differentially regulates mesenchymal and proneural signature genes in gliomas via STAT3 signaling.

Authors:  Kumar Natesh; Dipali Bhosale; Aarti Desai; Goparaju Chandrika; Radha Pujari; Jayashree Jagtap; Ashish Chugh; Deepak Ranade; Padma Shastry
Journal:  Neoplasia       Date:  2015-02       Impact factor: 5.715

4.  Development of a prognostic signature for esophageal cancer based on nine immune related genes.

Authors:  Zhi Zhang; Cheng Chen; Ying Fang; Sheng Li; Xiaohua Wang; Lei Sun; Guoren Zhou; Jinjun Ye
Journal:  BMC Cancer       Date:  2021-02-04       Impact factor: 4.430

5.  Murine Oncostatin M Has Opposing Effects on the Proliferation of OP9 Bone Marrow Stromal Cells and NIH/3T3 Fibroblasts Signaling through the OSMR.

Authors:  Lena Jakob; Tony Andreas Müller; Michael Rassner; Helen Kleinfelder; Pia Veratti; Jan Mitschke; Cornelius Miething; Robert A J Oostendorp; Dietmar Pfeifer; Miguel Waterhouse; Justus Duyster
Journal:  Int J Mol Sci       Date:  2021-10-28       Impact factor: 5.923

Review 6.  Oncostatin M: From Intracellular Signaling to Therapeutic Targets in Liver Cancer.

Authors:  Alessandra Caligiuri; Stefano Gitto; Giulia Lori; Fabio Marra; Maurizio Parola; Stefania Cannito; Alessandra Gentilini
Journal:  Cancers (Basel)       Date:  2022-08-30       Impact factor: 6.575

7.  Establish immune-related gene prognostic index for esophageal cancer.

Authors:  Caiyu Guo; Fanye Zeng; Hui Liu; Jianlin Wang; Xue Huang; Judong Luo
Journal:  Front Genet       Date:  2022-08-09       Impact factor: 4.772

Review 8.  Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma.

Authors:  Maria M Caffarel; Nicholas Coleman
Journal:  J Pathol       Date:  2014-03       Impact factor: 7.996

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.